Exelixis
EXEL
#1658
Rank
โ‚ฌ9.66 B
Marketcap
33,83ย โ‚ฌ
Share price
1.26%
Change (1 day)
72.60%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Revenue for Exelixis (EXEL)

Revenue in 2024 (TTM): โ‚ฌ1.90 Billion

According to Exelixis's latest financial reports the company's current revenue (TTM ) is โ‚ฌ1.94 Billion. In 2023 the company made a revenue of โ‚ฌ1.65 Billion an increase over the revenue in the year 2022 that were of โ‚ฌ1.50 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exelixis from 2000 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) โ‚ฌ1.90 B15.07%
2023 โ‚ฌ1.65 B10.23%
2022 โ‚ฌ1.50 B18.53%
2021 โ‚ฌ1.26 B57.82%
2020 โ‚ฌ0.80 B-7.06%
2019 โ‚ฌ0.86 B15.75%
2018 โ‚ฌ0.74 B97.91%
2017 โ‚ฌ0.37 B107.18%
2016 โ‚ฌ0.18 B435.39%
2015 โ‚ฌ33.99 M64.66%
2014 โ‚ฌ20.64 M-9.01%
2013 โ‚ฌ22.69 M-36.74%
2012 โ‚ฌ35.87 M-83.92%
2011 โ‚ฌ0.22 B60.31%
2010 โ‚ฌ0.13 B31.34%
2009 โ‚ฌ0.10 B25.64%
2008 โ‚ฌ84.3 M8.48%
2007 โ‚ฌ77.71 M3.92%
2006 โ‚ฌ74.77 M16.62%
2005 โ‚ฌ64.12 M64.56%
2004 โ‚ฌ38.96 M-4.82%
2003 โ‚ฌ40.93 M-3.45%
2002 โ‚ฌ42.39 M-8.68%
2001 โ‚ฌ46.43 M76.67%
2000 โ‚ฌ26.28 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
โ‚ฌ37.56 B 1,833.74%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ49.93 B 2,470.48%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ58.30 B 2,901.49%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ44.26 B 2,178.78%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ30.36 B 1,462.93%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ81.83 B 4,112.92%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ51.92 B 2,573.04%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ9.48 M-99.51%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ88.01 M-95.47%๐Ÿ‡บ๐Ÿ‡ธ USA